News headlines about NanoString Technologies (NASDAQ:NSTG) have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. NanoString Technologies earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6552726036416 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
NSTG has been the subject of several recent research reports. Robert W. Baird decreased their target price on shares of NanoString Technologies from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of NanoString Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Finally, ValuEngine cut shares of NanoString Technologies from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $15.06.
NanoString Technologies (NASDAQ:NSTG) traded up $0.21 during trading on Friday, reaching $7.00. 189,912 shares of the company traded hands, compared to its average volume of 130,669. NanoString Technologies has a 1-year low of $6.31 and a 1-year high of $20.70. The stock has a market capitalization of $172.35, a PE ratio of -3.38 and a beta of 0.78. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 1.08.
About NanoString Technologies
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.